What You Should Know:
– Abbott has received CE Mark (European approval) for its next-generation FreeStyle Libre 3 system for people with diabetes.
– FreeStyle Libre 3 is the latest advancement from Abbott’s FreeStyle Libre family of products and featuring the smallest, thinnest continuous glucose monitoring (CGM) sensor (~size of two stacked U.S. pennies) and a more environmentally sustainable system design.
Abbott, the worldwide leader in continuous glucose monitoring (CGM) technology, announced today it has secured CE Mark (Conformité Européenne) for its next-generation FreeStyle Libre 3 system, which is now approved for use by people living with diabetes in Europe. The FreeStyle Libre 3 technology provides continuous, real-time glucose readings automatically delivered to smartphones every minute, offering unsurpassed 14-day accuracy in the smallest and thinnest3 sensor design at the same affordable price as previous versions of the device. This is the first time Abbott has changed the sensor design since the initial FreeStyle Libre launch to be even more discreet for an enhanced user experience.
FreeStyle Libre 3 is the latest advancement from Abbott’s FreeStyle Libre family of products and features the following:
– The smallest, thinnest continuous glucose monitoring (CGM) sensor (~size of two stacked U.S. pennies) and a more environmentally sustainable system design
– Priced the same as previous generations of the device (which is ~70% less than other CGMs) to ensure as many people as possible living with diabetes have access
– The only CGM with real-time glucose readings and optional alarms automatically delivered to your smartphone every minute via the FreeStyle Libre 3 mobile app
– The longest-lasting, self-applied CGM available (14 days compared to other CGMs at 10 days) with unsurpassed performance and accuracy to make living with diabetes easier
Data also show use of the FreeStyle Libre system reduces diabetes-related hospital admissions and work absentee rates to help improve quality of life.
Availability
Abbott is launching the FreeStyle Libre 3 system in Europe in the coming months. The FreeStyle Libre portfolio has been clinically proven to improve glucose control, increase time in target glucose range, decrease time in hyperglycemia (high glucose levels) and hypoglycemia (low glucose levels), and lower HbA1c (average glucose levels over a three-month period) – all factors contributing to better health outcomes. Abbott has secured partial or full reimbursement for the FreeStyle Libre system in 37 countries, including Canada, France, Germany, Japan, the United Kingdom and the U.S.
“Abbott won’t stop innovating when there’s room to raise the bar. We’ve done that again with FreeStyle Libre 3, the smallest sensor that delivers life-changing benefits and best-in-class accuracy,” said Jared Watkin, senior vice president, Diabetes Care, Abbott. “People living with diabetes are at the center of our design process, and we made our next-generation technology even more discreet for a better user experience to make managing diabetes as easy and seamless as possible.”
“Since we launched the first disposable glucose sensor in 2014, we’ve always believed all people with diabetes should have access to high-quality, accurate and affordable diabetes technologies,” said Watkin. “That’s why Abbott disrupted the traditional notion that CGMs have to sacrifice quality or accuracy for affordability, and we built our FreeStyle Libre family of products to deliver unparalleled results at a lower cost than any other CGM available.”
